1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A.

    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

    LANCET . 403(10437): 1649-1659. Nº de citas: 4

    [doi:10.1016/S0140-6736(24)00054-0]

  • Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, DelNagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N.

    Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

    Clinical cancer research : an official journal of the American Association for Cancer Research . 30(8): 1630-1641.

    [doi:10.1158/1078-0432.CCR-23-2658]

  • Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK.

    Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

    JOURNAL OF CLINICAL ONCOLOGY . 42(11): 1222-1228. Nº de citas: 5

    [doi:10.1200/JCO.23.01569]

  • Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F.

    RET Fusion Testing in Patients With NSCLC: The RETING Study.

    Jto Clinical And Research Reports . 5(4): 100653-100653.

    [doi:10.1016/j.jtocrr.2024.100653]

  • Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME.

    Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.

    Breast . 74: 103681-103681.

    [doi:10.1016/j.breast.2024.103681]

  • Mínguez Ojeda C, Gómez Dos Santos V, Álvaro Lorca J, Ruz-Caracuel I, Pian H, Sanjuanbenito Dehesa A, Gutiérrez Gutiérrez E, Sanz Miguelañez JL, Pozo Mengual B, Burgos Revilla FJ, Araujo-Castro M.

    Surgery for adrenal metastasis: Surgical outcomes and prognostic factors for long-term survival.

    Annales d'endocrinologie . 85(2): 104-109.

    [doi:10.1016/j.ando.2024.01.010]

  • Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ.

    A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial.

    Future oncology (London, England) . 20(13): 799-809.

    [doi:10.2217/fon-2023-0755]

  • Albarrán V, San Román M, Pozas J, Chamorro J, Rosero DI, Guerrero P, Calvo JC, González C, García de Quevedo C, Pérez de Aguado P, Moreno J, Cortés A, Soria A.

    Adoptive T cell therapy for solid tumors: current landscape and future challenges.

    Frontiers in immunology . 15: 1352805-1352805.

    [doi:10.3389/fimmu.2024.1352805]

  • Tsukalov I, Sánchez-Cerrillo I, Rajas O, Avalos E, Iturricastillo G, Esparcia L, Buzón MJ, Genescà M, Scagnetti C, Popova O, Martin-Cófreces N, Calvet-Mirabent M, Marcos-Jimenez A, Martínez-Fleta P, Delgado-Arévalo C, de Los Santos I, Muñoz-Calleja C, Calzada MJ, González Álvaro I, Palacios-Calvo J, Alfranca A, Ancochea J, Sánchez-Madrid F, Martin-Gayo E.

    NF?B and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins.

    NATURE COMMUNICATIONS . 15(1): 2100-2100.

    [doi:10.1038/s41467-024-46322-8]

  • Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S.

    A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.

    CANCER MEDICINE . 13(5): . Nº de citas: 1

    [doi:10.1002/cam4.6776]

  • Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Percovich JC, García Centeno R, González L, Ollero García MD, Irigaray Echarri A, Moure Rodríguez MD, Novo-Rodríguez C, Calatayud M, Villar R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jimenéz C, Abellán Galiana P, Venegas Moreno E, González Molero I, Iglesias P, Blanco C, Vidal-Ostos De Lara F, de Miguel P, López Mezquita E, Hanzu F, Aldecoa I, Lamas C, Aznar S, Aulinas A, Calabrese A, Gracia P, Recio-Córdova JM, Aviles M, Asensio-Wandosel D, Sampedro M, Ruz-Caracuel I, Camara R, Paja M, Fajardo-Montañana C, Marazuela M, Puig-Domingo M.

    Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases.

    The Journal of clinical endocrinology and metabolism . : . Nº de citas: 3

    [doi:10.1210/clinem/dgae126]

  • Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA.

    Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

    Journal for ImmunoTherapy of Cancer . 12(2): . Nº de citas: 2

    [doi:10.1136/jitc-2023-007340]

  • Luque-Ramírez M, Nattero-Chávez L, Rodríguez-Rubio Corona C, Ortiz-Flores AE, García-Cano AM, Rosillo Coronado M, Pérez Mies B, Ruz Caracuel I, Escobar-Morreale HF.

    Postmenopausal onset of androgen excess: a diagnostic and therapeutic algorithm based on extensive clinical experience.

    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION . : .

    [doi:10.1007/s40618-023-02297-9]

  • Romero I, Guerra E, Madariaga A, Manso L.

    Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice.

    Frontiers in Oncology . 13: 1304303-1304303.

    [doi:10.3389/fonc.2023.1304303]

  • Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JÁF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MÁ, Mascareñas JL, Sainz B Jr.

    Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.

    Journal Of Experimental & Clinical Cancer Research . 43(1): 33-33. Nº de citas: 2

    [doi:10.1186/s13046-023-02931-7]

  • Menéndez V, Solórzano JL, García-Cosío M, Alonso-Alonso R, Rodríguez M, Cereceda L, Fernández S, Díaz E, Montalbán C, Estévez M, Piris MA, García JF.

    Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.

    SCIENTIFIC REPORTS . 14(1): 710-710.

    [doi:10.1038/s41598-024-51376-1]

  • Yilmaz O, Westerhoff M, Panarelli N, Hart J, Groisman G, Ruz-Caracuel I, Loughrey M, Matsukuma K, Lee SH, Yilmaz O, Gonzalez RS, Deshpande V.

    Lymphoglandular Complex-Like Colorectal Carcinoma-A Series of 20 Colorectal Cases, Including Newly Reported Features of Malignant Behavior.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 48(1): 70-79. Nº de citas: 1

    [doi:10.1097/PAS.0000000000002141]

  • Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Gorp TV, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V.

    Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

    JOURNAL OF CLINICAL ONCOLOGY . 41(35): 5400-5410. Nº de citas: 2

    [doi:10.1200/JCO.22.02906]